Core Viewpoint - Guangyuyuan (600771.SH) reported a significant increase in revenue for the third quarter, but a substantial decline in net profit, indicating potential challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 281 million yuan in the third quarter, representing a year-on-year increase of 20.31% [1] - The net profit attributable to shareholders was 2.0269 million yuan, showing a year-on-year decrease of 82.16% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 7.8907 million yuan, down 16.84% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan [1]

证券代码：600771 证券简称：广誉远 编号：临 2025-018 广誉远中药股份有限公司 第八届董事会第十八次会议决议公告 特此公告。 广誉远中药股份有限公司董事会 二〇二五年十月二十四日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十八次会议于 2025 年 10 月 14 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2025 年 10 月 24 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及《公 司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了《公司 2025 年第三季度报告》。 《公司 2025 年第三季度报告》已经董事会审计委员会审议通过，同意提交公司董 事会审议。 表决情况：同意 6 票，反对 0 票，弃权 0 票。 特别提示 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥281,439,240.27, representing a year-on-year increase of 20.31%[4] - The total profit for the third quarter was ¥31,440,622.14, showing a significant increase of 87.44% compared to the same period last year[4] - The net profit attributable to shareholders of the listed company was ¥2,026,883.66, reflecting a decrease of 82.16% year-on-year[4] - The basic earnings per share for the third quarter was ¥0.0041, down 82.16% from the same period last year[5] - Total operating revenue for the first three quarters of 2025 reached ¥1,060,722,805.38, an increase of 18.7% compared to ¥893,525,764.69 in the same period of 2024[22] - Net profit for the first three quarters of 2025 was ¥82,154,595.05, compared to ¥80,327,259.54 in 2024, indicating a slight increase of 2.3%[23] - Total comprehensive income for the first three quarters of 2025 reached ¥82,154,595.05, a slight increase from ¥80,327,259.54 in the same period of 2024, representing a growth of 2.28%[24] - The company reported a basic and diluted earnings per share of ¥0.16 for the first three quarters of 2025, up from ¥0.14 in 2024, reflecting a growth of 14.29%[24] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥201,284,927.31, which increased by 47.95% compared to the previous year[4] - The company's cash and cash equivalents increased to ¥296,435,376.70 as of September 30, 2025, compared to ¥116,672,133.81 at the end of 2024[17] - Cash and cash equivalents at the end of the first three quarters of 2025 totaled ¥295,098,692.52, compared to ¥135,999,306.73 at the end of the same period in 2024, marking an increase of 117.91%[28] - Net cash flow from operating activities for the first three quarters of 2025 was ¥201,284,927.31, compared to ¥136,053,785.23 in 2024, indicating an increase of 47.94%[27] - Total cash inflow from operating activities was ¥1,132,450,883.45 in 2025, down from ¥1,197,449,684.17 in 2024, a decrease of 5.42%[26] - Cash outflow from operating activities decreased to ¥931,165,956.14 in 2025 from ¥1,061,395,898.94 in 2024, a reduction of 12.29%[27] - The company incurred cash outflows from financing activities of ¥8,921,932.44 in 2025, significantly lower than ¥254,705,483.04 in 2024, indicating a decrease of 96.49%[27] - Investment activities resulted in a net cash outflow of ¥12,651,299.96 in 2025, compared to a smaller outflow of ¥2,300,178.09 in 2024[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 65,306[11] - The largest shareholder, Shennong Technology Group Co., Ltd., holds 74,233,468 shares, accounting for 15.17% of total shares[11] - The company has not reported any significant changes in the top 10 shareholders or their shareholding status due to margin trading activities[12] - The company’s controlling shareholder, Shennong Technology Group, plans to increase its stake by investing between ¥50 million and ¥100 million over a 12-month period, having already acquired 2,724,500 shares, representing 0.56%[13] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,460,513,055.05, an increase of 8.11% from the end of the previous year[5] - The company's total assets as of September 30, 2025, amounted to ¥2,460,513,055.05, an increase from ¥2,275,876,460.56 at the end of 2024[20] - Total liabilities increased to ¥788,839,141.46 as of September 30, 2025, compared to ¥685,165,602.02 at the end of 2024, representing a growth of 15.1%[19] - The total equity attributable to shareholders reached ¥1,648,692,320.07 as of September 30, 2025, up from ¥1,569,808,332.85 at the end of 2024, reflecting a growth of 5.0%[20] Tax and Penalties - The decline in net profit for the third quarter was primarily due to a tax payment of ¥23,971,187.08 and late fees totaling ¥5,694,189.20[9] - A subsidiary, Tibet Guangyuyuan Pharmaceutical Co., Ltd., paid a total of ¥29,665,376.28 in tax and penalties, which will impact the company's net profit for 2025[15] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥31,043,139.71, compared to ¥27,910,261.53 in 2024, marking an increase of 11.5%[22] Strategic Focus - The company attributed the profit growth to increased sales and effective cost control measures implemented during the period[9] - The company continues to focus on optimizing product strategy and maintaining performance-driven growth as part of its "1541" strategy[9] Financial Reporting - The company’s financial statements for the quarter ending September 30, 2025, are unaudited[16] - The company’s total assets and liabilities will be detailed in the upcoming audited financial report for 2025[15]

Core Viewpoint - Guangyuyuan reported a third-quarter revenue of 281 million yuan, representing a year-on-year increase of 20.31%, while net profit decreased by 82.16% to 2.0269 million yuan [1] Financial Performance - For the third quarter, revenue reached 281 million yuan, up 20.31% year-on-year [1] - Net profit for the third quarter was 2.0269 million yuan, down 82.16% compared to the previous year [1] - For the first three quarters, total revenue was 1.061 billion yuan, reflecting an 18.71% year-on-year growth [1] - Net profit for the first three quarters amounted to 78.884 million yuan, which is an increase of 11.16% year-on-year [1]

Core Insights - Guangyuyuan has established a three-in-one operational model for its boutique traditional Chinese medicine business, which includes "National Medicine Hall, National Medical Museum, and Museum" [1] - The company aims to create a comprehensive health service ecosystem by integrating e-commerce platforms, internet hospitals, physical hospitals, flagship pharmacies, and cultural museums through digital infrastructure [1] - As of June 30, 2025, the total number of terminal stores is expected to exceed 500 [1] Company Overview - Guangyuyuan is one of the oldest traditional Chinese medicine companies, with its origins dating back to 1541 [1] - The company is listed on the Shanghai Stock Exchange (stock code 600771) and focuses on the production and sales of traditional Chinese medicine, boutique Chinese medicine, and health wine [1] - In 2021, Guangyuyuan re-entered the Shanxi state-owned asset system and aims to become a leading enterprise in high-quality traditional Chinese medicine [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 779 million yuan, representing a year-on-year increase of 18.14% [2] - The net profit attributable to shareholders of the listed company was 76.86 million yuan, up 28.95% year-on-year [2]

Core Viewpoint - Guangyuyuan's stock price has shown a slight increase this year, with a notable rise in recent trading days, indicating potential investor interest and market activity [1][2]. Group 1: Stock Performance - As of October 16, Guangyuyuan's stock price increased by 2.04%, reaching 19.47 CNY per share, with a trading volume of 45.14 million CNY and a turnover rate of 0.48%, resulting in a total market capitalization of 9.53 billion CNY [1]. - Year-to-date, Guangyuyuan's stock price has risen by 3.23%, with a 2.26% increase over the last five trading days, but has seen a decline of 2.55% over the past 20 days and 3.80% over the last 60 days [2]. Group 2: Company Overview - Guangyuyuan, established on November 25, 1996, and listed on November 5, 1996, is located in Taiyuan, Shanxi Province, and specializes in the production and sale of traditional Chinese medicine, premium Chinese medicine, and health wines [2]. - The company's revenue composition includes 72.19% from traditional Chinese medicine, 24.20% from premium Chinese medicine, 3.55% from health wines, and 0.06% from other sources [2]. - Guangyuyuan operates within the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector, and is associated with concepts such as new retail, pharmaceutical e-commerce, and Alzheimer's [2]. Group 3: Financial Performance - For the first half of 2025, Guangyuyuan reported a revenue of 779 million CNY, reflecting a year-on-year growth of 18.14%, while the net profit attributable to shareholders was 76.86 million CNY, marking a 28.95% increase [2]. - The company has cumulatively distributed 12.71 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 4: Shareholder Information - As of June 30, 2025, Guangyuyuan had 63,500 shareholders, a decrease of 5.12% from the previous period, with an average of 7,708 circulating shares per shareholder, which is an increase of 5.40% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 5.62 million shares, while Southern CSI 1000 ETF and Huaxia CSI 1000 ETF have increased their holdings [3].

Core Viewpoint - The article discusses ongoing legal actions against Yili Clean Energy (亿利洁能) and Guangyuyuan (广誉远) for alleged financial misconduct and false statements, with investors seeking compensation for losses incurred due to these actions [1][2][3]. Group 1: Yili Clean Energy (亿利洁能) - Yili Clean Energy is facing multiple investor compensation claims due to false statements and financial misconduct, with cases submitted to the Hohhot Intermediate People's Court [1]. - The company has been accused of financial fraud from 2016 to 2022, including inflating profits, assets, and revenues, as well as providing guarantees to controlling shareholders and related parties [1]. - The company allegedly engaged in fraudulent bond issuance and misled investors regarding its financial health [1]. Group 2: Guangyuyuan (广誉远) - Guangyuyuan is also under scrutiny for false disclosures related to its sales practices from 2016 to 2021, including improper revenue recognition and mismanagement of sales expenses [2]. - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, may still initiate compensation claims [3]. - The company has been found to have misrepresented its "buyout sales" model, leading to significant inaccuracies in its annual reports [2].

Core Insights - The article highlights the significance of the Hunyuan Astragalus industry in promoting rural revitalization and its potential to evolve into a "billion-level industry" through collaboration and modernization [6][7]. Group 1: Industry Development - Hunyuan County is recognized as the origin of "Hengshan Astragalus," with a history of over 1500 years in harvesting and processing, benefiting from favorable environmental conditions [1]. - The "Hundred-Person Team" initiative aims to enhance the quality and standards of Hengshan Astragalus through collaboration with leading pharmaceutical companies [1][3]. - The local government is committed to integrating the Astragalus industry with agriculture, aiming to boost economic advantages and support rural development [6]. Group 2: Collaboration and Innovation - The initiative has attracted major companies like Beijing Tongrentang and JD Health, focusing on establishing long-term supply mechanisms and enhancing product quality [3][6]. - Various stakeholders propose innovative product forms and marketing strategies to cater to younger consumers and expand market reach [4][3]. - The establishment of a comprehensive standard system for planting, quality testing, and traceability is emphasized to ensure the integrity of the product [3][6]. Group 3: Economic Impact - The collaboration is expected to increase income for local farmers, with 50,000 households currently engaged in the Astragalus industry [7]. - The total output value of the Hengshan Astragalus industry has reached 1.5 billion yuan, with products exported to over 60 countries [6][7]. - The initiative aims to create more job opportunities through the extension of the industry chain and the integration of technology and policy support [7].

Core Insights - The event successfully integrated traditional Chinese medicine (TCM) heritage with modern health concepts, showcasing the "Taigu Longevity Code" as a practical modern health guide [1][9] - The activity highlighted the importance of cultural heritage in promoting public health and wellness, aligning with the "Healthy China" strategy [1][8] Group 1: Cultural Heritage and Innovation - The event featured immersive experiences that challenged public stereotypes about TCM, with demonstrations of traditional production techniques by national-level intangible cultural heritage inheritors [3][5] - The innovative transformation of traditional techniques was exemplified by the reduction of the traditional 49-day refining process to just 17 days using modern technology, reflecting the principle of "innovation without forgetting the roots" [5][6] Group 2: Public Engagement and Education - Interactive games were used to educate the public about TCM principles, making the learning process engaging and accessible [6][7] - Experts debunked common misconceptions about health practices, promoting a scientific understanding of wellness that combines traditional wisdom with modern medical insights [7][8] Group 3: Health Practices and Longevity - The presence of elderly intangible cultural heritage inheritors demonstrated the practical benefits of TCM, showcasing how lifestyle choices contribute to longevity [7][9] - The sharing of specific health practices, such as moderate consumption of medicinal wine and balanced diets, provided actionable insights for healthy aging [7][9] Group 4: Cultural and Economic Impact - The event served as a model for integrating cultural tourism with health industry development, highlighting the role of traditional medicine in modern society [8][9] - The collaboration among heritage inheritors, medical experts, and the public illustrated a collective effort necessary for advancing the "Healthy China" initiative [8][9]

Group 1 - The core point of the article is the resignation of the financial director and the appointment of a new financial director at Guangyuyuan Pharmaceutical Co., Ltd. due to work adjustments [1] - The board of directors received resignation reports from financial director Wang Junbo and vice president Ren Yan, with Wang Junbo remaining as vice president [1] - The board's nomination committee and audit committee approved the proposal to appoint Ren Yan as the new financial director, with a term until the end of the eighth board of directors [1] Group 2 - For the first half of 2025, Guangyuyuan's revenue composition is as follows: pharmaceutical industry accounts for 89.39%, other businesses 3.85%, and health wine 3.29% [1]